Lake Street analyst Ben Haynor initiated coverage of Tactile Systems (TCMD) with a Buy rating and $23.50 price target The firm, which believes 15M-25M patients are collectively afflicted with lymphedema or bronchiectasis in the U.S., thinks only 10%-20% have been diagnosed and notes that Tactile is “the market leader” in pneumatic compression devices for LE and that the company’s AffloVest holds a number two share position in high-frequency chest wall oscillation devices for BE. Coverage headwinds have abated for Tactile and recent strategic optimizations set it up for a growth reacceleration in 2026, the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TCMD:
- Tactile Systems Technology’s Mixed Q2 Earnings Call
- Tactile Systems price target raised to $13 from $12 at B. Riley
- Buy Recommendation for Tactile Systems Technology: Strong Q2 Performance and Strategic Restructuring Drive Positive Outlook
- Tactile Systems Technology Reports Q2 2025 Growth
- Tactile Systems reports Q2 EPS 14c, consensus 14c